Premium
Butalbital and Pediatric Headache: Stay off the Downward Path
Author(s) -
Caruso Alessandra,
Lazdowsky Lori,
Rabner Jonathan,
Haberman Jason,
LeBel Alyssa
Publication year - 2015
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.12484
Subject(s) - medicine , path (computing) , anesthesia , pediatrics , computer science , computer network
Despite limited evidence from the literature surrounding safety or efficacy, butalbital‐containing medicines ( BCM s) have maintained their rank as “go‐to” prescribed migraine and headache relief drugs in the U nited S tates, despite bans on these barbiturates in G ermany and other E uropean countries. Providers at the P ediatric H eadache P rogram at B oston C hildren's H ospital recommend that clinicians prescribe triptan‐based medications instead of BCM s, given the known negative side effects of BCM s on the general population, and the uncertain longitudinal trajectory of BCM s on developing brains.